<?xml version="1.0" encoding="UTF-8"?>
<p>ADE development should also be considered as possible adverse effects of hyperimmune globulin therapy and vaccine development. Duan and co‐workers (
 <xref rid="cytoa24047-bib-0049" ref-type="ref">49</xref>) successfully used convalescent plasma collected from cured patients with a titer of 1:640 SARS‐CoV‐2‐NAbs for transfusion into COVID‐19 patients. While this study was successful in terms of abolishing viral load in 7 of 10 patients together with augmenting saturation by oxyhemoglobin, declining immune response, minimally increased lymphocyte count and partially reduced lung lesions (
 <xref rid="cytoa24047-bib-0049" ref-type="ref">49</xref>), the efficacy is unclear as no control treatment was included.
</p>
